Milestone Pharmaceuticals (MIST) Corporate presentation summary

Product overview and clinical need

• CARDAMYST (etripamil) is a novel, FDA-approved calcium channel blocker nasal spray for acute conversion of PSVT to sinus rhythm in adults.

• PSVT affects over 2 million people in the US, with significant healthcare costs exceeding $5 billion annually.

• Current PSVT treatments are inconvenient, with no new drug therapies approved since 1989.

• CARDAMYST offers fast onset, robust clinical data, and is well tolerated with up to 36 months shelf life.

• Patent protection extends until 2042.

Market opportunity and strategy

• Commercial launch began in February, targeting new patient starts, prescription growth, and commercial coverage.

• No anticipated branded competition and a low barrier to prescribing.

• Approximately 1 million PSVT patients are treated annually, with half managed by 10,000 healthcare providers.

• Initial sales force covers 50% of the annually treated patient population.

• Market access strategy includes payer engagement, retail distribution, and copay savings programs.

Clinical and economic impact

• CARDAMYST enables fast, reliable self-administration, reducing reliance on emergency departments.

• Clinical studies show a ~40% reduction in emergency department use for PSVT.

• 24% of PSVT ED visits result in hospital admission, highlighting cost-saving potential.

• Prescriber and patient support programs facilitate adoption and fulfillment.

• Key performance indicators include new-to-brand prescriptions, prescription growth, and quality coverage.